EMA Authorised: Carvykti (ciltacabtagene autoleucel) — Janssen-Cilag International NV

View source ↗

Summary

EMA has authorised Carvykti (ciltacabtagene autoleucel) for the treatment of multiple myeloma. The product is a CAR-T therapy developed by Janssen-Cilag Interna…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carvykti (ciltacabtagene autoleucel)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: Janssen-Cilag International NV. Decision date: 10/02/2026. Orphan medicine